Eagle Asset Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-457,077
| Closed | -$78.7M | – | 637 |
|
|
2021
Q3 | $78.7M | Sell |
457,077
-3,176
| -0.7% | -$415K | 0.36% | 108 |
|
|
2021
Q2 | $57.8M | Sell |
460,253
-153
| -0% | -$19.3K | 0.25% | 142 |
|
|
2021
Q1 | $63.5M | Sell |
460,406
-277,134
| -38% | -$35.8M | 0.28% | 136 |
|
|
2020
Q4 | $94.4M | Sell |
737,540
-64,463
| -8% | -$7.56M | 0.53% | 49 |
|
|
2020
Q3 | $90.7M | Sell |
802,003
-96,897
| -11% | -$9.65M | 0.47% | 83 |
|
|
2020
Q2 | $86.4M | Buy |
898,900
+294,046
| +49% | +$28.3M | 0.49% | 74 |
|
|
2020
Q1 | $54.4M | Sell |
604,854
-309,549
| -34% | -$24.1M | 0.34% | 111 |
|
|
2019
Q4 | $48.5M | Sell |
914,403
-4,955
| -0.5% | -$226K | 0.23% | 166 |
|
|
2019
Q3 | $36.3M | Buy |
919,358
+11,028
| +1% | +$478K | 0.19% | 182 |
|
|
2019
Q2 | $37.3M | Buy |
908,330
+29,753
| +3% | +$1.23M | 0.19% | 189 |
|
|
2019
Q1 | $40.9M | Buy |
878,577
+988
| +0.1% | +$43.4K | 0.22% | 178 |
|
|
2018
Q4 | $38.2M | Sell |
877,589
-4,570
| -0.5% | -$228K | 0.24% | 168 |
|
|
2018
Q3 | $50.5M | Sell |
882,159
-6,252
| -0.7% | -$307K | 0.24% | 170 |
|
|
2018
Q2 | $43.1M | Sell |
888,411
-338,285
| -28% | -$12.3M | 0.23% | 165 |
|
|
2018
Q1 | $48M | Sell |
1,226,696
-3,282
| -0.3% | -$140K | 0.26% | 141 |
|
|
2017
Q4 | $52.2M | Sell |
1,229,978
-15,073
| -1% | -$565K | 0.29% | 119 |
|
|
2017
Q3 | $47.1M | Sell |
1,245,051
-11,591
| -0.9% | -$402K | 0.27% | 132 |
|
|
2017
Q2 | $38.2M | Buy |
1,256,642
+77,683
| +7% | +$2.25M | 0.23% | 155 |
|
|
2017
Q1 | $31.2M | Buy |
1,178,959
+4,100
| +0.3% | +$108K | 0.2% | 164 |
|
|
2016
Q4 | $30M | Buy |
1,174,859
+367,884
| +46% | +$11.7M | 0.2% | 157 |
|
|
2016
Q3 | $29.2M | Buy |
806,975
+83,146
| +11% | +$2.75M | 0.2% | 162 |
|
|
2016
Q2 | $24.6M | Sell |
723,829
-52,627
| -7% | -$1.71M | 0.17% | 178 |
|
|
2016
Q1 | $20.5M | Buy |
+776,456
| New | +$22.6M | 0.14% | 209 |
|
Eagle Asset Management's XLRN Position: Q4 2021 in Review
Eagle Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 457,077 shares — an estimated $78.7M sold.
Eagle Asset Management first reported a position in XLRN in Q1 2016 and held it in 23 quarters. The position peaked at $94.4M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Eagle Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Eagle Asset Management sold 457,077 Acceleron Pharma shares in Q4 2021, an estimated $78.7M.
- Eagle Asset Management first reported a position in Acceleron Pharma in Q1 2016 and held it in 23 quarters.
- Eagle Asset Management's Acceleron Pharma position peaked at $94.4M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Eagle Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.